Jade Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapies for patients with autoimmune diseases, with a focus on improving treatment convenience and efficacy compared to existing options. The company's lead program, JADE101, is an extended half-life anti-APRIL antibody targeting IgA nephropathy, a common kidney disease affecting millions of patients globally, designed to enable less frequent dosing while offering superior potency. Jade operates a highly specialized development model by outsourcing manufacturing and supply chain activities to partners, allowing the company to concentrate resources on research and commercialization, and generates future revenue through upfront payments, milestone fees, and royalties from its drug candidates.